Put another way, the absolute risk of experiencing an atypical thigh-bone fracture was one in 1,000 among women taking a bone-building medication for five years or more, said lead author Laura Park-Wyllie, a pharmaceutical and outcomes researcher at St. Michael's Hospital in Toronto.